New results for single stage low energy carbon AMS

Klody, G.M.; Schroeder, J.B.; Norton, G.A.; Loger, Roger; Kitchen, R.L.; Sundquist, M. L.

doi:10.1016/j.nimb.2005.06.168

Cited by 19 publications

(15 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis by AMS requires conversion of samples via a two-step process of oxidation to CO 2 and then reduction to graphite (Vogel, 1992). The AMS provides an isotope ratio of [ (Klody et al, 2005). A carbon content of control plasma of 4.38%, previously established using a Costech Carbon Analyzer (Valencia, CA), was used as the basis for the carbon content of all plasma samples analyzed.…”

Section: Accelerator Mass Spectrometry Analysesmentioning

confidence: 99%

Disposition and Metabolism of GSK2251052 in Humans: A Novel Boron-Containing Antibiotic

Bowers¹,

Tenero²,

Patel³

et al. 2013

Drug Metab Dispos

View full text Add to dashboard Cite

ABSTRACT(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (GSK2251052) is a novel boron-containing antibiotic that inhibits bacterial leucyl tRNA synthetase, and that has been in development for the treatment of serious Gramnegative infections. In this study, six healthy adult male subjects received a single i.v. dose of [ 14 C]GSK2251052, 1500 mg infused over 1 hour. Blood, urine, and feces were collected over an extended period of 14 days, and accelerator mass spectrometry was used to quantify low levels of radioactivity in plasma at later time points to supplement the less-sensitive liquid scintillation counting technique. An excellent mass balance recovery was achieved representing a mean total of 98.2% of the dose, including 90.5% recovered in the urine. Pharmacokinetic analysis demonstrated that radioactivity was moderately associated with the blood cellular components, and together with GSK2251052, both were highly distributed into tissues. The parent compound had a much shorter half-life than total radioactivity in plasma, approximately 11.6 hours compared with 96 hours. GSK2251052 and its major metabolite M3, which resulted from oxidation of the propanol side chain to the corresponding carboxylic acid, comprised the majority of the plasma radioactivity, 37 and 53% of the area under the plasma versus time concentration curve from time zero to infinity, respectively. Additionally, M3 was eliminated renally, and was demonstrated to be responsible for the long plasma radioactivity elimination half-life. A combination of in vitro metabolism experiments and a pharmacokinetic study in monkeys with the inhibitor 4-methylpyrazole provided strong evidence that alcohol dehydrogenase, potentially in association with aldehyde dehydrogenase, is the primary enzyme involved in the formation of the M3 metabolite.

show abstract

Section: Accelerator Mass Spectrometry Analysesmentioning

confidence: 99%

Disposition and Metabolism of GSK2251052 in Humans: A Novel Boron-Containing Antibiotic

Bowers¹,

Tenero²,

Patel³

et al. 2013

Drug Metab Dispos

View full text Add to dashboard Cite

show abstract

“…In April 2014, we completed the installation of a 250 kV SSAMS purchased from National Electrostatics Corporation[11]. Figure 4 shows a schematic of our newly christened “BioDeck” laboratory, which is configured with a 250 kV SSAMS with two MCGSNICS gas-accepting ion sources, each with a copy of our moving wire interface for the analysis of small liquid samples.…”

Section: Biodeckmentioning

confidence: 99%

Operation of the “Small” BioAMS spectrometers at CAMS: Past and future prospects

Ognibene

Haack

Bench

et al. 2015

Nuclear Instruments and Methods in Physics Research Section B:

View full text Add to dashboard Cite

A summary of results from the solid samples run on our compact 1 MV AMS system over its 13.5 years of operation is presented. On average 7065 samples per year were measured with that average dropping to 3278 samples per year following the deployment of our liquid sample capability. Although the dynamic range of our spectrometer is 4.5 orders in magnitude, most of the measured graphitic samples had 14C/C concentrations between 0.1 and 1 modern. The measurements of our ANU sucrose standard followed a Gaussian distribution with an average of 1.5082 ± 0.0134 modern. The LLNL biomedical AMS program supported many different types of experiments, however, the large majority of samples measured were derived from animal model systems. We have transitioned all of our biomedical AMS measurements to the recently installed 250 kV SSAMS instrument with good agreement compared in measured 14C/C isotopic ratios between sample splits. Finally, we present results from replacement of argon stripping gas with helium in the SSAMS with a 22% improvement in ion transmission through the accelerator and high-energy analyzing magnet.

show abstract

“…Over 10 user-defined parameters allow the user to customize the ALGI operation, such as gas flow rates, background 14 C event threshold limits, and gas line evacuation time. The radio carbon measurements were done on an NEC 250 kV Single Stage AMS (SSAMS) open air deck [8].…”

Section: Design and Control Systemmentioning

confidence: 99%